Hoth Therapeutics Story

<div class='circular--portrait' style='background:#FF6600;color: #FFFAFA;font-size:4em;'>HT</div>
HOTH -- USA Stock  

USD 2.32  0.08  3.57%

53% of stocks are less volatile than Hoth Therapeutics, and 91% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. While some risk-seeking stockholders are getting worried about healthcare space, it is reasonable to concentrate on Hoth Therapeutics as a possible investment alternative. We will go over odds for Hoth Therapeutics to generate above-average margins next quarter.
Published over two weeks ago
View all stories for Hoth Therapeutics | View All Stories
Is Hoth Therapeutics (NASDAQ:HOTH) rise feasible based on current volatility?
The current Average Equity is estimated to decrease to about 3.8 MHoth Therapeutics has a current ratio of 18.69, suggesting that it is liquid enough and is able to pay its financial obligations when due. On a scale of 0 to 100, Hoth Therapeutics holds a performance score of 6. The company retains a Market Volatility (i.e. Beta) of -0.1097, which attests to not very significant fluctuations relative to the market. Let's try to break down what Hoth Therapeutics's beta means in this case. As returns on the market increase, returns on owning Hoth Therapeutics are expected to decrease at a much lower rate. During the bear market, Hoth Therapeutics is likely to outperform the market. Although it is vital to follow Hoth Therapeutics current price history, it is good to be conservative about what you can do with the information regarding equity current price movements. The philosophy towards determining future performance of any stock is to evaluate the business as a whole together with its past performance, including all available fundamental and technical indicators. We have found twenty-one technical indicators for Hoth Therapeutics, which you can use to evaluate the performance of the firm. Please utilizes Hoth Therapeutics information ratio, potential upside, as well as the relationship between the Potential Upside and kurtosis to make a quick decision on whether Hoth Therapeutics current trending patterns will revert.
Volatility is a rate at which the price of Hoth Therapeutics or any other equity instrument increases or decreases for a given set of returns. It is measured by calculating the standard deviation of the annualized returns over a given period of time and shows the range to which the price of Hoth Therapeutics may increase or decrease. In other words, similar to Hoth Therapeutics's beta indicator, it measures the risk of Hoth Therapeutics and helps estimate the fluctuations that may happen in a short period of time. So if prices of Hoth Therapeutics fluctuate rapidly in a short time span, it is termed to have high volatility, and if it swings slowly in a more extended period, it is understood to have low volatility. Please read more on our technical analysis page.

How important is Hoth Therapeutics's Liquidity

Hoth Therapeutics financial leverage refers to using borrowed capital as a funding source to finance Hoth Therapeutics ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Hoth Therapeutics financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Hoth Therapeutics's total debt and its cash.

How Hoth Therapeutics utilizes its cash?

To perform a cash flow analysis of Hoth Therapeutics, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Hoth Therapeutics is receiving and how much cash it distributes out in a given period. The Hoth Therapeutics cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities. Hoth Therapeutics Net Cash Flow from Operations is most likely to decrease significantly in the upcoming years. The last year's value of Net Cash Flow from Operations was reported at (4.45 Million)

Hoth Therapeutics Volatility Drivers

Hoth Therapeutics unsystematic risk is unique to Hoth Therapeutics and usually not directly affected by the market or economic environment. An example of unsystematic risk is the possibility of poor earnings or a layoff due to coronavirus. One may mitigate nonsystematic risk by buying different securities in the same industry or by buying in different sectors. For example, if you have a position in Hoth Therapeutics you can also buy Auris Medical Holding. You can also mitigate this risk by investing in the biotechnology sector as well as in companies having nothing to do with it. This type of risk is also called diversifiable risk and can be understood from analyzing Hoth Therapeutics important indicators over time. Here we run a correlation analysis between relevant fundamental ratios over at least ten year period to find a relationship in the way they react to changes in Hoth Therapeutics income statement and balance sheet. Here are more details about Hoth Therapeutics volatility.
Click cells to compare fundamentals   

Acquisition by Linsley Wayne of 15000 shares of Hoth Therapeutics subject to Rule 16b-3

Legal trades by Hoth Therapeutics insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Hoth Therapeutics insider trading alert for grant of options by Linsley Wayne, the corporate stakeholder, on 23rd of July 2020. This event was filed by Hoth Therapeutics Inc with SEC on 2020-07-23. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Breaking down Hoth Therapeutics Indicators

Net Loss for the year was (10.35 M).

Our perspective of the current Hoth Therapeutics rise

Downside variance is down to 5.59. It may hint to a possible volatility drop. Hoth Therapeutics is displaying above-average volatility over the selected time horizon. Investors should scrutinize Hoth Therapeutics independently to ensure intended market timing strategies are aligned with expectations about Hoth Therapeutics volatility.

Our Takeaway on Hoth Therapeutics Investment

While other companies under the biotechnology industry are still a bit expensive, Hoth Therapeutics may offer a potential longer-term growth to stockholders. While some stockholders may not share our view we believe that the current risk-reward utility is not appealing enough to do any trading. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Hoth Therapeutics.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Achuva Shats do not own shares of Hoth Therapeutics. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to